In addition, IFN-γ-related gene signatures predicted clinical response to programmed cell death protein 1 (PD-1)/programmed cell death 1 ligand 1 (PD-L1)-inhibiting therapeutic agents in breast cancer [15] and in other malignancies [16]. Here, PDCD1 is linked to breast carcinoma.